US Stock MarketDetailed Quotes

ICCM Icecure Medical

Watchlist
  • 1.360
  • -0.010-0.73%
Close Feb 14 16:00 ET
  • 1.370
  • +0.010+0.74%
Post 19:10 ET
76.93MMarket Cap-4.86P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Feb 4 07:36
    NEWS
    $Icecure Medical (ICCM.US)$
    IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision
    Tuesday, 4th February at 8:30 am
    Two independent studies of ProSense® cryoablation in breast cancer were presented, one of which won the Highest Scoring Abstract Award in its category
    Hands-on ProSense® training featured during the S...
    Trytosaveabit
    Trytosaveabit
    Jan 27 07:37
    update
    $Icecure Medical (ICCM.US)$ Icecure Files for Regulatory Approval of Prosense® Cryoablation System in China
    Jaguar8
    Jaguar8
    Jan 27 07:31
    NEWS
    $Icecure Medical (ICCM.US)$
    IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China
    Monday, 27th January at 8:30 am
    Seeks to expand regulatory approval in China where IceSense3 has already been approved
    CAESAREA, Israel, Jan. 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, t...
    Jaguar8
    Jaguar8
    Jan 13 06:03
    NEWS
    $Icecure Medical (ICCM.US)$
    IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America
    Monday, 13th January at 7:00 am
    Increase in sales of ProSense®, based on preliminary unaudited results, demonstrate growing adoption of ProSense® cryoablation for breast tumors.
    FDA decision on market authorization of ProSense® for early-stage breast cancer is expected in the first quarter of 2025.
    FDA Advisory Panel voted in favor of ProSense®'...
Read more
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
Petroleo Brasileiro SA Petrobras
PBR
+4.45%
Strategy
MSTR
+3.94%
Vale SA
VALE
+1.99%
KB Home
KBH
+1.28%
Apple
AAPL
+1.27%

Unlock the Full List